Connect with us

Drug Manufacturers - General

Rubicon Research Limited (RUBICON) gains 10% intraday, clears resistance

Rubicon Research Limited (RUBICON) stock moves up 10% intraday, breaking out above its 6-month resistance trendline at ₹1646.

adit chauhan author tradealone

Published

on

Rubicon Research Limited RUBICON clears resistance

Rubicon Research Limited (RUBICON) breaks out with a +10% gain to ₹1788.0 on the NSE on 17 Aug 2026, clearing its 6M resistance trendline. This move comes on the back of the company’s recent corporate announcements, including the Monitoring Agency Report for the quarter ended June 30, 2026. Rubicon, a key player in the healthcare sector under Drug Manufacturers – General, has shown strong momentum, though today’s move appears to be more company-specific rather than a broad sector rally.

Technical setup — trendlines & DMA

From a technical standpoint, Rubicon Research has established a robust 6M trendline structure. The 6M support trendline ends at ₹1610.99, which is 9.90% below today’s price, indicating a solid floor. The resistance trendline, previously at ₹1645.76, has been decisively broken, with the stock now trading 7.96% above this level. The 50-DMA at ₹1423.2 is comfortably above the 200-DMA at ₹936.8, signaling a bullish trend. However, the stock is currently 14% above the 50-DMA, suggesting it may be stretched. In the 52W range of ₹570.8 to ₹1684.1, the stock is in the upper third, indicating that a substantial portion of the move may already be priced in.

6M Trendline — Intraday Snapshot
BREAKOUT₹1,000₹1,200₹1,400₹1,60018 May17 Jun17 Jul17 Aug

Snapshot: ₹1,788.00 on 2026-08-17 (chart frozen at publication)

Fundamentals & business context

On the fundamental front, Rubicon Research’s PE of 105.3, coupled with profit margins of 14.1% and a revenue CAGR of 36.6% over the past five years, suggests that the market is pricing in significant growth expectations. However, the absence of profit CAGR over the same period raises questions about the sustainability of these high valuations. Institutional ownership stands at 12.3%, indicating a cautious approach by smart money, possibly due to the high PE and the lack of profit growth. There is no specific NSE catalyst today beyond the routine corporate announcements.

RUBICON
Holdings Analysis
Key strengths & risk signals
68
Overall
42
Fundamental
94
Technical
Risks (2)
Cannot calculate PEG - insufficient growth data.
OVERBOUGHT! RSI at 78.5 - caution, may pull back.
Strengths (3)
BULLISH TREND! 50-day average (888.9) is above 200-day average (751.7) - positive signal.
BREAKOUT! Stock has broken above resistance levels with momentum.
EXCELLENT YEAR! Stock gained 60.1% in the last year.

Algorithmic scorecard

The algorithmic scorecard paints a picture of a stock that is technically strong but fundamentally weak. The overall score reflects this dichotomy, with the technical score highlighting a bullish trend and breakout, while the fundamental score points to declining revenue and profit growth, negligible dividend yield, and insufficient historical data for stability analysis. The two strongest signals are the bullish trend, with the 50-day average above the 200-day average, and the breakout above resistance levels with momentum. These indicate systematic accumulation and positive market sentiment. Conversely, the two weakest signals are the declining revenue and profit CAGR, and the negligible dividend yield, which represent risks of unsustainable growth expectations and lack of income generation for investors.

Fundamental & Technical AnalysisNSE: RUBICON
68Overall
42Fundamental
94Technical
Growth Quality4 / 30
Revenue CAGR: 0% (DECLINING, 2/15). Profit CAGR: 0% (DECLINING, 2/15).
Profit Margin5 / 10
DECENT EFFICIENCY! 12.9% profit margin - acceptable profitability.
PEG Valuation1 / 10
Cannot calculate PEG - insufficient growth data.
Dividend Yield3 / 10
NEGLIGIBLE DIVIDEND! 0% yield - little to no income.
Debt / Equity10 / 10
VERY LOW DEBT! D/E of 0.00 - excellent financial health.
Public Holding14 / 20
MODERATE PUBLIC HOLDING! 22.57% public ownership - balanced ownership structure.
Stability5 / 10
Insufficient historical data for stability analysis.
Moving Averages12 / 10
BULLISH TREND! 50-day average (888.9) is above 200-day average (751.7) - positive signal.
Price Position8 / 10
STRONG POSITION! Current price (1171.1) is above both moving averages.
Trend Pattern20 / 20
BREAKOUT! Stock has broken above resistance levels with momentum.
52W Performance10 / 10
EXCELLENT YEAR! Stock gained 60.1% in the last year.
Volume Sentiment30 / 30
BULLISH SENTIMENT! In last 30 days: 17 up days, 13 down days. Avg volume on up days: 429,517 vs down days: 177,463. Ratio: 2.42x
RSI2 / 5
OVERBOUGHT! RSI at 78.5 - caution, may pull back.
52W Range5 / 5
STRONG! Trading at 94.4% of 52W range - near yearly highs.
Momentum4 / 5
GOOD MOMENTUM! Price has grown across all timeframes - up 24.0% (1 week), 20.7% (1 month), 51.4% (3 months).
Beta / Volatility3 / 5
MARKET ALIGNED! Beta of 1.00 - moves with the market.

Company outlook

Management’s forward guidance for Rubicon Research is optimistic, with strong revenue visibility and growth momentum expected in the coming quarters. The EBITDA range is projected to remain between 22% to 23%, and R&D spend guidance for the next nine quarters is set at a high-confidence level of INR 5 billion. The company plans a capital expenditure of INR 800 million for the year, with an additional INR 300 crores planned for the next two years across various sites. Key initiatives include ramping up the Pithampur facility in Q1 of CY 2027 and the acquisition of Arinna Lifesciences to build a global therapeutics platform around CNS and chronic conditions.

Get all details on RUBICON — P&L, peers, shareholding and more on TradeAlone.

Drug Manufacturers - General

Sms Pharmaceuticals Limited Q2fy27: Revenue Up 30% Yoy, PAT Up 57% to ₹40 Crore

SMS Pharmaceuticals Limited (NSE: SMSPHARMA) reports a 30% YoY revenue growth and a 57% increase in PAT for Q2FY27, driven by strong volume growth and improv.

Pranab Tyagi at TradeAlone

Published

on

Sms Pharmaceuticals Limited Q2fy27 Results: Revenue Up 30% Yoy, PAT Up 57% to ₹40 Crore

SMS Pharmaceuticals Limited (NSE: SMSPHARMA), a diversified and integrated pharmaceutical company specializing in Complex Active Pharmaceutical Ingredients (APIs) and intermediates for global customers, is pleased to announce its unaudited financial results for the quarter and half year ended September 30, 2026. The company delivered a strong second quarter that exceeded expectations, driven by higher volumes and improved price realization across its product portfolio.

Financial Highlights

Revenue from operations for Q2FY27 grew 30% YoY and 53% QoQ to ₹316.08 crore. Growth was primarily driven by anti-inflammatory APIs, ARVs, and favorable pricing dynamics. For H1FY27, revenue expanded 19% YoY to ₹523.05 crore. Excluding the anti-diabetic segment, H1FY27 revenue grew 38% YoY, reflecting a favorable portfolio shift.

Gross Margin and EBITDA

Gross profit (Incl. manufacturing expenses) for Q2FY27 rose 41% YoY to ₹110.84 crore. Gross Margin expanded 268 bps YoY to 35%, underpinned by backward integration and an increased share of high-value APIs. EBITDA increased 40% YoY to ₹67.65 crore, with EBITDA margins expanding 145 bps YoY to 21%, aided by operating leverage.

Profit After Tax

PAT grew 57% YoY to ₹39.57 crore, delivering a PAT margin of 13%. Share of profit from associate entity, VKT Pharma Private Limited, stood at ₹0.28 crore in Q2FY27. For H1FY27, EBITDA grew 24% YoY to ₹108.60 crore (EBITDA margin of 21%), while PAT rose 36% YoY to ₹59.76 crore. Share of profit from associate entity, VKT Pharma Private Limited, stood at ₹0.99 crore in H1FY27.

Based on our H1FY27 performance and outlook for the rest of the year, we are now confident of exceeding our earlier guidance. We completed six DMF/CEP filings in FY27 to date; on track to meet the full-year target of 10 DMF/CEP filings in FY27. Additionally, our ₹280 crore capital expenditure program remains on track for completion by FY27.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of SMS Pharmaceuticals Limited

SMS Pharmaceuticals Limited belongs to the › sector. Here’s a quick read on where the business and the stock stand today.

SMSPHARMA
Healthcare › Drug Manufacturers - General
APPROACHING RESISTANCE
58
Fundamental
88
Technical
73
Overall

1W +1.91%
1M +19.92%
3M +40.6%
P/E: 40.2 Cap: Small
AI-Powered Analysis • TradeAlone
Download the App for in-depth analysis of this stock

SMS gains 16.2% over three months and trades near its 52-week highs. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. No meaningful dividend — total return is entirely dependent on capital appreciation. Buyers show up with 2.2x the volume of sellers. Moreover, they dominated on 16 of recent sessions versus 14 for sellers — a healthy accumulation pattern. The stock rises 16.2% in three months on 19.3% revenue growth. As a result, the market gives it more credit than the fundamentals strictly justify. Watch the next quarterly results. If growth accelerates, the move makes sense. If not, expect some gains to unwind. Check Fundamentals of SMS Pharmaceuticals Limited.

Continue Reading

Drug Manufacturers - General

Marksans Pharma Limited (marksans) Q2 & H1 FY27: Record Revenue & Profitability Surge

Marksans Pharma Limited (MARKSANS) reports record Q2 & H1 FY27 results with revenue crossing ₹900 crore and PAT nearly doubling.

abhinav tiwari

Published

on

Marksans Pharma Limited Marksans Q2 FY27 Results

Marksans Pharma Limited (NSE: MARKSANS) reported financial results for Q2 and H1 FY27, marking a significant milestone with quarterly revenue crossing ₹900 crore for the first time. The company’s Q2FY27 EBITDA surged 48% to a record ₹214 crore, while H1FY27 PAT nearly doubled to ₹303 crore. Mark Saldanha, Founder, Chairman & Managing Director, highlighted the company’s strong performance, driven by broad-based growth across all regions.

Q2FY27 Highlights

In Q2FY27, Marksans Pharma’s operating revenue reached ₹940 crore, up 30.5% year-on-year (YoY). Adjusted for acquisition impact, revenue growth remained robust at 25%. EBITDA grew 48.3% to ₹214 crore, with margins expanding by 274 basis points to 22.8%. Notably, the UK & Europe market grew 64.9% to a record ₹405 crore, while the US & North America segment delivered its highest-ever quarter at ₹421 crore.

H1FY27 Performance

For H1FY27, revenue grew 32.9% to ₹1,781 crore. EBITDA rose 74.7% with margins up 574 basis points to 24.0%, and PAT nearly doubled to ₹303 crore. The company’s operating cash flow reached ₹322 crore, 4.3 times the previous year, and cash balances closed at ₹1,124 crore. Marksans Pharma’s trailing twelve-month return on capital employed (ROCE) improved to 24.7%.

Mark Saldanha emphasized the company’s expanding global footprint, robust product pipeline, and strong net-cash position. ‘We enter the next phase of our growth journey from a position of considerable strength,’ he said. ‘Our focus remains on sustaining profitable organic growth while selectively pursuing strategic acquisitions that strengthen our capabilities and market presence. We remain confident in our growth trajectory and committed to creating sustainable long-term shareholder value.’

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Marksans Pharma Limited

Marksans Pharma Limited belongs to the › sector. Here’s a quick read on where the business and the stock stand today.

MARKSANS
Healthcare › Drug Manufacturers - General
CONSOLIDATING DOWN
72
Fundamental
74
Technical
73
Overall

1W +4.87%
1M +1.38%
3M -4.35%
P/E: 25.8 Cap: Mid
AI-Powered Analysis • TradeAlone
Download the App for in-depth analysis of this stock

Marksans gains 16.4% over three months and trades near its 52-week highs. The business compounds revenue at 16.7% and profits at 16.2% CAGR. That is strong double-digit growth on both counts. Not a single revenue dip or loss quarter in five years — this is a business built to last through cycles. The stock gives back 1.7% in the last month despite a positive three-month run. As a result, the earlier momentum appears to be fading. Revenue grows at 16.7% and profits at 16.2%. The business is in good shape. Moreover, a stock that does not move despite strong fundamentals often offers better value than one already priced for perfection. Check Fundamentals of Marksans Pharma Limited.

Continue Reading

Drug Manufacturers - General

Glaxosmithkline Pharmaceuticals Limited (glaxo) Q2 FY27: Growth Surges with Key Portfolio Transformation

GlaxoSmithKline Pharmaceuticals Limited (GLAXO) reports Q2 FY27 growth, driven by portfolio transformation and innovation.

Pranab Tyagi at TradeAlone

Published

on

Glaxosmithkline Pharmaceuticals Limited GLAXO Q2 FY27 Results

GlaxoSmithKline Pharmaceuticals Limited (GLAXO) showcased robust growth in Q2 FY27, driven by strategic portfolio transformation and innovation. The company’s performance highlights the successful execution of its growth strategy, with key metrics reflecting significant advancements across various segments.

Key Financial Highlights

GLAXO’s revenue for Q2 FY27 surged by 21%, reaching ₹1,180 crore, while the first half of the fiscal year saw a 18% increase to ₹2,104 crore. The company’s EBITDA for Q2 FY27 stood at ₹400 crore, marking a 20% growth from the previous year. Notably, the PAT (profit after tax) before exceptional items grew by 33% to ₹335 crore, contributing to a margin improvement of 260 basis points to 29%.

Market Performance and Portfolio Strength

The pharmaceutical portfolio of GLAXO maintained its leadership, with a 25% share in the representative market. The General Medicines and Vaccines segments continued to outperform, with key brands like Augmentin, Calpol, and Neosporin showing significant unit growth rates. The Vaccines segment, particularly Shingrix, doubled in sales, driven by effective engagement with healthcare providers and organizations.

Future Outlook

Looking ahead, GLAXO remains committed to its growth trajectory through continued portfolio transformation and innovation. The company is set to launch new products in Oncology, Respiratory, and Adult Vaccines, aiming to further strengthen its market position and deliver sustained growth.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of GlaxoSmithKline Pharmaceuticals Limited

GlaxoSmithKline Pharmaceuticals Limited belongs to the › sector. Here’s a quick read on where the business and the stock stand today.

GLAXO
Healthcare › Drug Manufacturers - General
BREAKOUT
82
Fundamental
68
Technical
76
Overall

1W +5.85%
1M +5.27%
3M -0.6%
P/E: 39.5 Cap: Large
AI-Powered Analysis • TradeAlone
Download the App for in-depth analysis of this stock

GlaxoSmithKline posts a 4.5% three-month gain, but softens in the last few weeks. Industry-leading margins of 27.0% reflect exceptional pricing power and operational efficiency. The PEG of 2.11 is on the high side. However, it is acceptable for a quality compounder with a strong moat. The stock gives back 10.2% in the last month despite a positive three-month run. As a result, the earlier momentum appears to be fading. The business grows revenue at 5.7% and profits at 19.3%, with D/E of 0.01. The stock reflects that strength. Moreover, when fundamentals and price action align, the PEG of 2.11 premium is usually justified. Check Fundamentals of GlaxoSmithKline Pharmaceuticals Limited.

Continue Reading

Trending